Pages that link to "Q37510624"

The following pages link to Structural homology of corticotropin-releasing factor, sauvagine, and urotensin I: circular dichroism and prediction studies (Q37510624):

Displaying 22 items.

• Residues of corticotropin releasing factor-binding protein (CRF-BP) that selectively abrogate binding to CRF but not to urocortin 1 (Q24308848) (← links)
• A receptor-binding region in human choriogonadotropin/lutropin beta subunit (Q24613369) (← links)
• NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor1 receptor (Q27643440) (← links)
• Structure of the N-terminal domain of a type B1 G protein-coupled receptor in complex with a peptide ligand (Q27644056) (← links)
• A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists (Q28572089) (← links)
• Cloning and characterization of teneurin C-terminus associated peptide (TCAP)-3 from the hypothalamus of an adult rainbow trout (Oncorhynchus mykiss). (Q31065185) (← links)
• Potent, structurally constrained agonists and competitive antagonists of corticotropin-releasing factor (Q33785575) (← links)
• Corticotropin releasing hormone: therapeutic implications and medicinal chemistry developments. (Q33969367) (← links)
• The binding protein of corticotropin-releasing factor: ligand-binding site and subunit structure (Q34155179) (← links)
• Chemical neuroimmunology: health in a nutshell bidirectional communication between immune and stress (limbic-hypothalamic-pituitary-adrenal) systems (Q35148867) (← links)
• Peripheral corticotropin-releasing factor receptor type 2 activation increases colonic blood flow through nitric oxide pathway in rats (Q35564811) (← links)
• Corticotropin-releasing factor peptide antagonists: design, characterization and potential clinical relevance (Q37662647) (← links)
• Secondary structure of antisauvagine analogues is important for CRF receptor antagonism: development of antagonists with increased potency and receptor selectivity (Q40697071) (← links)
• High-affinity binding of urocortin and astressin but not CRF to G protein-uncoupled CRFR1. (Q40909880) (← links)
• Peptide hormone evolution: functional heterogeneity within GnRH and CRF families (Q41350674) (← links)
• Interaction of an amphiphilic peptide with a phospholipid bilayer surface by molecular dynamics simulation study (Q41677831) (← links)
• Intracisternal sauvagine is more potent than corticotropin-releasing factor to decrease gastric vagal efferent activity in rats (Q41689003) (← links)
• An optimized solid phase synthesis strategy--including on-resin lactamization--of astressin, its retro-, inverso-, and retro-inverso isomers as corticotropin releasing factor antagonists (Q43851708) (← links)
• Constrained Corticotropin-Releasing Factor Antagonists withi-(i 3) Glu−Lys Bridges (Q46042603) (← links)
• Adrenocorticotropic hormone‐releasing activity of urotensin I and its fragments in vitro (Q48623404) (← links)
• Sauvagine-like and corticotropin-releasing factor-like immunoreactivity in the brain of the bullfrog (Rana catesbeiana) (Q68097352) (← links)
• Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs (Q73443059) (← links)